Drug intelligence / Profile preview

NORDBIOTIC FeMAX

Development stage: Preclinical
Lead developer: Nordic Biotic
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

NORDBIOTIC FeMAX is a probiotic-based dietary supplement developed by Nordic Biotic to support iron absorption and address iron deficiency. The formulation consists of a multilayer tablet containing two specific probiotic strains, *Lacticaseibacillus casei* (NORDBIOTIC™ LC130) and *Lacticaseibacillus paracasei* (NORDBIOTIC™ LPC100), combined with an innovative iron source. The mechanism of action involves a pH-related modulation in the gut environment that enhances the solubility and bioavailability of iron, potentially reducing the gastrointestinal side effects typically associated with high-dose iron supplementation. As of early 2024, the product is in the preclinical stage, with in vitro studies supporting its efficacy in improving iron availability.

Brand names: NORDBIOTIC FeMAX
Other names: NORDBIOTIC LC130 + NORDBIOTIC LPC100 + iron

Beyond the preview

Go deeper on NORDBIOTIC FeMAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NORDBIOTIC FeMAX.

Explore the full profile